Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03703167 · ClinicalTrials.gov registry record · Phase 1

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

A Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL), sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
7
Study locations

NCT03703167 is a Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL) that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants, below the 178-participant average among 5 other Primary Central Nervous System Lymphoma (PCNSL) trials with a reported enrollment target (86% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03703167, a Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL), has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
7
Study locations

Study Summary

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

Conditions Studied

Primary Central Nervous System Lymphoma (PCNSL) Secondary Central Nervous System Lymphoma (SCNSL)

Interventions

  • DRUG Rituximab
  • DRUG Lenalidomide
  • DRUG Ibrutinib

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2019-01-22
Est. Completion 2026-01-26
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03703167

The ClinicalTrials.gov registry entry for NCT03703167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 5 other Primary Central Nervous System Lymphoma (PCNSL) trials with a reported enrollment target (86% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Primary Central Nervous System Lymphoma (PCNSL) appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT03703167 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03703167 about?

NCT03703167 is a clinical study titled "Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)". The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

What is the current status of trial NCT03703167?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-01-22. Estimated completion is 2026-01-26.

What conditions does trial NCT03703167 study?

This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL).

What interventions are being tested in trial NCT03703167?

The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT03703167?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03703167 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Central Nervous System Lymphoma (PCNSL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Central Nervous System Lymphoma (PCNSL)

All registered trials for this condition

Secondary Central Nervous System Lymphoma (SCNSL)

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.